Today: Today, Pacira Pharmaceuticals Inc. (PCRX) Receives “Market Perform” Rating from BMO Capital Markets

Today, Pacira Pharmaceuticals Inc. (PCRX) Receives “Market Perform” Rating from BMO Capital Markets

Pacira Pharmaceuticals Inc. (NASDAQ:PCRX)‘s stock had its “market perform” rating restated by equities researchers at BMO Capital Markets in a note issued to investors on Saturday. They currently have a $35.00 price objective on the stock. BMO Capital Markets’ target price indicates a potential upside of 6.54% from the stock’s current price.

Several other research firms have also weighed in on PCRX. Zacks Investment Research raised Pacira Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective for the company in a research note on Wednesday, August 10th. Brean Capital reissued a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Friday, August 5th. Cowen and Company began coverage on Pacira Pharmaceuticals in a research note on Wednesday, September 7th. They set a “market perform” rating for the company. Wedbush reissued an “outperform” rating and set a $109.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, September 21st. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $81.00 price objective on shares of Pacira Pharmaceuticals in a research note on Wednesday, August 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seven have assigned a buy rating to the stock. Pacira Pharmaceuticals has an average rating of “Hold” and a consensus target price of $71.18.

Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 1.23% during trading on Friday, hitting $32.85. The stock had a trading volume of 477,441 shares. The company has a 50-day moving average of $34.21 and a 200 day moving average of $38.86. The firm’s market cap is $1.23 billion. Pacira Pharmaceuticals has a 52-week low of $30.25 and a 52-week high of $80.25.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.22. The business earned $68.40 million during the quarter, compared to analyst estimates of $67.16 million. Pacira Pharmaceuticals had a negative return on equity of 1.52% and a negative net margin of 13.37%. The company’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $0.32 EPS. On average, equities research analysts predict that Pacira Pharmaceuticals will post $0.55 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in PCRX. BNP Paribas Arbitrage SA raised its position in Pacira Pharmaceuticals by 111.3% in the third quarter. BNP Paribas Arbitrage SA now owns 3,051 shares of the company’s stock valued at $104,000 after buying an additional 1,607 shares during the period. BlackRock Inc. raised its position in Pacira Pharmaceuticals by 60.5% in the second quarter. BlackRock Inc. now owns 4,007 shares of the company’s stock valued at $135,000 after buying an additional 1,510 shares during the period. Acrospire Investment Management LLC raised its position in Pacira Pharmaceuticals by 2,000.0% in the third quarter. Acrospire Investment Management LLC now owns 4,200 shares of the company’s stock valued at $144,000 after buying an additional 4,000 shares during the period. US Bancorp DE raised its position in Pacira Pharmaceuticals by 8.5% in the second quarter. US Bancorp DE now owns 5,010 shares of the company’s stock valued at $169,000 after buying an additional 394 shares during the period. Finally, Teacher Retirement System of Texas raised its position in Pacira Pharmaceuticals by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 5,184 shares of the company’s stock valued at $175,000 after buying an additional 622 shares during the period.

Pacira Pharmaceuticals Company Profile

Related posts

Leave a Comment